Neusignal Therapeutics, Inc.
PrivateLast Round
Series B
Jun 30, 2026
Total Funding Raised
$49.32M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Neusignal Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in Tokyo. Its latest recorded funding round was a Series B round in June 2026.
Neusignal Therapeutics, Inc. is a biotechnology company that develops small-molecule oral drugs for the treatment of dementia and other central nervous system diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neusignal Therapeutics, Inc. Comparables
Compare Neusignal Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Asceneuron | 84% | |
| AriBio | 83% | |
| NeuroTherapia, Inc. | 81% |
For institutional investors. Book with your work email.
Neusignal Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 30, 2026 | ||||
| Series A | Jan 31, 2025 | ||||
| Seed | Mar 1, 2024 | ||||
| Seed | Sep 1, 2022 |
For institutional investors. Book with your work email.
Neusignal Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| THE GOGIN CAPITAL Co., Ltd. | Series B |
| Angel Bridge | Series B |
| Keio Innovation Initiative | Series B, Seed, Series A |
| Mizuho Capital | Seed, Series A |
| Red Capital | Series B |
| DCI Partners | Series B |
| 日本ベンチャーキャピタル株式会社 | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2026
$33M round led by Angel Bridge and DCI Partners.
- Jan 31, 2025
$7.34M round with SMBC Venture Capital and others.
For institutional investors. Book with your work email.
Neusignal Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neusignal Therapeutics, Inc.'s valuation, stock price, and market status.
Is Neusignal Therapeutics, Inc. a public or private company?
Neusignal Therapeutics, Inc. is a private company.
What is the current stock price of Neusignal Therapeutics, Inc.?
Neusignal Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Neusignal Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neusignal Therapeutics, Inc. worth (valuation)?
Valuation information for Neusignal Therapeutics, Inc. is not publicly available.
Can I buy Neusignal Therapeutics, Inc. stock?
Neusignal Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neusignal Therapeutics, Inc.'s last funding round?
Neusignal Therapeutics, Inc.'s most recent funding round was Series B on June 30, 2026.
Who are the main investors in Neusignal Therapeutics, Inc.?
Key investors in Neusignal Therapeutics, Inc. include Angel Bridge, DCI Partners.
Will Neusignal Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Neusignal Therapeutics, Inc..
How can I track Neusignal Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Neusignal Therapeutics, Inc.'s shares on secondary markets.